DALIAN, China -- Major Chinese drugmakers are rushing to expand production capacity for COVID-19 vaccines to aid inoculation drives around the world, but mounting doubts over how well their shots work may cloud global demand down the line.
Hammering sounds reverberated across a Beijing construction site one June day as workers put up walls for a new Sinopharm-affiliated vaccine factory. "Construction is going on 24 hours a day so the plant can go online July 1," a security guard said.
